9115 Hague Road
Founded in 1896, Roche is a global pioneer in pharmaceuticals and diagnostics and is the world’s largest biotech company, focused on advancing science to improve people’s lives. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics. The Diagnostics division develops and produces medical tests that provide information to help healthcare professionals find the right treatment for patients and deliver the best patient care to improve, prolong and save lives.
We offer a wide range of research and in vitro (outside the body) diagnostic tools that help in the early detection, prevention, diagnosis and treatment of diseases like congestive heart failure, HIV, hepatitis and diabetes, as well as medical conditions like fertility and blood coagulation. These products and services are used by researchers, physicians, patients, healthcare facilities and laboratories around the world.
Roche Diagnostics has its North American headquarters in Indianapolis. The Roche campus, located at 96th Street and Hague Road, spans about 155 acres and is home to U.S. research and development, laboratory, manufacturing, distribution, IT and administrative operations. The campus supports six diagnostics business areas: Diabetes Care, Centralized Diagnostics, Sequencing and Life Science, Molecular Diagnostics, Point of Care Diagnostics and Tissue Diagnostics. About 4,000 employees report into Indianapolis, with about 2,900 working onsite.
Roche Molecular Solutions, one of the global business areas within Roche Diagnostics, brings together the diagnostic power of molecular, tissue and sequencing technologies.
With the goal of revolutionizing diagnostic decisions through integrated solutions, Roche Molecular Solutions brings together the latest technologies withinmolecular diagnostics (polymerase chain reaction or PCR-based testing), tissue diagnostics (tissue biopsy testing) and sequencing solutions (next-generation DNA and RNA sequence-based testing) to advance the standard of care for everyone.
4300 Hacienda Drive
Pleasanton, California 94588
1780 articles with Roche
Roche Partners with iHeartMedia to Present 'iHeartCountry One Night For Our Military' Concert to Bring Further Awareness of The Impact Diabetes Has On The Nation's Veteran Population
Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has again partnered with iHeartMedia, the number one audio company in the United States, to present the iHeartCountry One Night For Our Military concert on Thursday, November 7,1 at the Country Music Hall of Fame in Nashville
Staying Ahead of Biosimilar Competition, Roche's Rituxan Shows Superiority in Rare Autoimmune Ski...
10/14/2019Roche announced results from its Phase III PEMPHIX trial evaluated MabThera/Rituxan (rituximab) compared to mycophenolate mofetil (MMF) in adults with moderate to severe pemphigus vulgaris.
Roche Vice Chairman Andre Hoffman is warning that short-term thinking is killing the planet and that corporations must engage in long-term sustainable strategies that limit any environmental harm and can help reverse some of the damage that’s already been done.
Bayer Vital with its subsidiary Jenapharm is the “Best Pharmaceutical Company” in the 2019 Pharma Trend Ranking. Novartis Pharma and Roche Pharma take second and third place, respectively, followed by Janssen-Cilag and Bristol-Myers Squibb.
GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.
According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.
BioSpace, the leader in life sciences news and careers, today announced that Genentech, Pfizer, Merck, Amgen and Novartis landed in the top five spots of their latest Ideal Employer report.
Researchers from Genentech and its parent company Roche have developed what is being called the first “deep learning model” that can predict which patients with diabetic retinopathy will progress the fastest.
50 million people worldwide live with symptomatic Alzheimer's, which has no cure. In honor of September 21st being World Alzheimer's Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.
9/16/2019Last week was a busy one for clinical trial results, particularly with the European Committee for Treatment and Research in Multiple Sclerosis 2019 Congress going on. Here’s a look at some of the top clinical trial stories.
The company presented the data at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
KAHR Medical Announces Clinical Trial Collaboration to Evaluate DSP107 in Combination With a PD-L1 Checkpoint Inhibitor in Advanced Lung Cancer Patients
KAHR Medical announced a new clinical collaboration with Roche.
9/9/2019Last week was a busy week for clinical trial results. Here’s a look at some of the top stories and reporting.
This week, Roche said it extended its tender-offer period for outstanding shares of Spark to Oct. 1 from Sept. 3.
Survey of Benefits Decision-Makers About the Burden of Diabetes in the Workplace Reveals Sleepless Nights, Secrets and Solutions
In the silence of the night, seven out of ten benefits decision-makers at US employers are awake seeking a solution for the financial and human burden of diabetes management, according to the findings of a new survey.
Genentech said Phase III data from the BLOCKSTONE study showed that an individual treated with Xofluza after being exposed to the flu by an infected household member, reduced the risk of developing the flu by 86% compared to placebo.
8/23/2019Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments.
Sandra Horning, Roche’s chief medical officer and head of global product development, will retire from the company at the end of the year, leaving some big shoes to fill.
Although some of the top-selling drugs in the world are facing patent cliffs between now and then, many of them are still projected to continue being big sellers between now and 2024.
The FDA approved Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, Rozlytrek secured accelerated approval for the treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance...